Market Newsdesk

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced that it will host a KOL webinar on the potential of briquilimab in chronic urticaria on Wednesday, October 11, 2023 at 8:00 AM Eastern Standard Time.

The event will feature Dr. Stephen Galli, Dr. Marcus Maurer, and Dr. Jeffrey Ravetch who will discuss the current treatment landscape and unmet medical need for patients suffering from chronic urticaria, as well as Jasper’s briquilimab as a potential therapeutic.

Jasper’s leadership team will also provide an overview of upcoming clinical studies which will evaluate briquilimab’s potential as a therapeutic for both CSU patients and CIndU patients. Briquilimab is an unconjugated aglycosylated anti-c-Kit antibody that blocks the interaction of the c-Kit receptor from its ligand, stem cell factor (SCF). This mechanism of action disrupts the critical survival signal, leading to mast cell apoptosis thereby removing the underlying source of the inflammatory response in chronic urticaria.

“We’re proud to have assembled a distinguished panel of biologic and clinical experts to provide their invaluable perspective on mast cell biology, on treatment options for mast cell-driven diseases such as chronic urticarias, and on the therapeutic potential of monoclonal antibodies such as briquilimab,” said Ronald Martell, President and Chief Executive Officer of Jasper.  “Mast cell depletion stands at the biologic forefront of mast cell-driven diseases like CSU and CIndU with the potential to provide deep and durable control of disease symptoms. The briquilimab clinical studies in CSU and CIndU are designed to identify the optimal biologic dose and the optimal dosing schedule based on the biology of the mast cell and briquilimab’s unique profile.”

Dr. Stephen Galli is Professor of Pathology, Microbiology and Immunology and the Mary Hewitt Loveless, M.D. Professor at Stanford Medicine. Dr. Galli leads the Galli Laboratory at Stanford Medicine, a lab focused on developing and employing innovative approaches to understanding the development and function of mast cells and basophils. He is also a member of the Executive Committee of the Stanford Institute for Immunity, Transplantation and Infection.

Dr. Marcus Maurer is Professor of Dermatology and Allergy and the executive Director of the Institute of Allergology at the Charité – Universitätsmedizin Berlin. Dr. Maurer is board certified in Dermatology and Allergology and is also the Co-Director of Allergology and Immunology at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP.

Dr. Jeffrey Ravetch is currently the Theresa and Eugene Lang Professor at the Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology. His laboratory has focused on the Fc domain of antibodies and their receptors, establishing their structural and functional diversity and the pre-eminence of FcR pathways in host defense, inflammation and tolerance. His work has been widely extended into clinical applications for the treatment of neoplastic, inflammatory and infectious diseases.

A live question and answer session with management will follow the formal presentations. To register for the event, please click here.

About Briquilimab

Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven disease such as chronic urticaria. Jasper intends to start clinical studies of briquilimab as a primary treatment in Chronic Spontaneous Urticaria as well as in Chronic Inducible Urticaria. Briquilimab is also currently in clinical studies as a treatment for patients with Low to Intermediate Risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell and gene therapies for rare diseases. To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in severe combined immunodeficiency (SCID), acute myeloid leukemia (AML), MDS, Fanconi anemia (FA), and sickle cell disease (SCD).

About Jasper

Jasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases such as chronic urticaria and lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for stem cell transplants for rare diseases such as sickle cell disease (SCD), Fanconi anemia (FA) and severe combined immunodeficiency (SCID). To date, briquilimab has a demonstrated efficacy and safety profile in more than 145 dosed participants and healthy volunteers, with clinical outcomes as a conditioning agent in SCID, acute myeloid leukemia (AML), MDS, FA, and SCD. For more information, please visit us at www.jaspertherapeutics.com.

Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab’s potential, the development of briquilimab for CSU, CIndU, LR-MDS and stem cell transplant conditioning; the briquilimab clinical studies in the treatment of CSU and CIndU; and Jasper’s expectations regarding the results of the studies, including the potential to identify optimal doses and dosing schedules. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical studies may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper’s product candidates may not be beneficial to patients or successfully commercialized; patients’ willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper’s business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper’s business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022 and any subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper’s assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts:

John Mullaly (investors)
LifeSci Advisors
617-429-3548
[email protected]

Herb Cross (investors)
Jasper Therapeutics
408-621-5925
[email protected]

Lauren Barbiero (media)
Real Chemistry
646-564-2156
[email protected]

ALHAMBRA, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) — EMCORE Corporation (Nasdaq: EMKR), the world’s largest independent provider of inertial navigation solutions to the aerospace and defense industry, announced today the advancement of Photonic Integrated Chip (PIC) technology and integration into all of the Company’s open-loop FOG-based products.

PIC technology resulted from three years of development and began integration into EMCORE’s previous generation open-loop designs in late 2021 through 2022, culminating with the launch of the TAC-450 Inertial Measurement Unit (IMU), EMCORE’s first IMU series with PIC Inside™, and the new TAC-450 single- and multi-axis FOGs.

The PIC enables significantly improved reliability, unit-to-unit repeatability, durability, outstanding shock/vibration tolerance, and easier integration for exceptional navigation capability and environmental robustness in challenging applications. The technology is based on the groundbreaking integrated optical chip that replaces individual fiber optic components with a silicon waveguide system that results in improved optical performance by simplifying the handmade optical couplers, polarizers, and two splices incorporated within a gyro assembly.

“Our PIC-based products are transforming EMCORE’s inertial sensor tactical product platform with more products sharing common software, electronics, and circuit boards,” said Matthew Vargas, Vice President of Sales for EMCORE. “We’ve seen broad acceptance in the market with the greater flexibility to tailor these precision PIC-based FOGs and IMUs to our customer’s needs,” added Mr. Vargas.

EMCORE is now introducing a program for customers of previous-generation open-loop FOG, IMU, and INS products to upgrade to a PIC-based unit. This includes the DSP-3000 series, DSP-17xx products, and GEO-FOG INS. The replaced optical circuit will then carry a new 1-year warranty.

EMCORE will be exhibiting at the Association of the United States Army (AUSA) Annual Meeting & Exposition October 9-11 in Washington, DC, booth #2715. For further discussion and specifications, call +1 866-234-4976; e-mail [email protected]; or visit us on the web: www.emcore.com.

About EMCORE

EMCORE Corporation is a leading provider of inertial navigation products for the aerospace and defense markets. We leverage industry-leading Photonic Integrated Chip (PIC), Quartz MEMS, and Lithium Niobate chip-level technology to deliver state-of-the-art component and system-level products across our end-market applications. EMCORE has vertically-integrated manufacturing capability at its facilities in Alhambra, CA, Budd Lake, NJ, Concord, CA, and Tinley Park, IL. Our manufacturing facilities all maintain ISO 9001 quality management certification, and we are AS9100 aerospace quality certified at our facilities in Alhambra, Budd Lake, and Concord. For further information about EMCORE, please visit https://www.emcore.com.

Forward-looking statements:

The information provided herein may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include statements regarding EMCORE’s plans, strategies, goals and business prospects, growth opportunities, changes, and trends in our business and expansion into new markets. These forward-looking statements are based on management’s current expectations, estimates, forecasts, and projections about EMCORE and are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements, including without limitation, the following: (a) the rapidly evolving markets for our products and uncertainty regarding the development of these markets; (b) our historical dependence on sales to a limited number of customers and fluctuations in the mix of products and customers in any period; (c) the effect of component shortages and uncertainties concerning the availability and cost of commodity materials and specialized product components that we do not make internally; (d) delays and other difficulties in commercializing new products; (e) the failure of new products: (i) to perform as expected without material defects, (ii) to be manufactured at acceptable volumes, yields, and cost, (iii) to be qualified and accepted by our customers, and (iv) to successfully compete with products offered by our competitors; (f) actions by competitors; and (g) other risks and uncertainties discussed under Item 1A – Risk Factors in our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, as updated by our subsequent periodic reports. Forward-looking statements contained in this press release are made only as of the date hereof, and EMCORE undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

EMCORE Corporation

Matthew Vargas
Vice President of Sales
(401) 408-4096
[email protected]

Investor

Tom Minichiello
Chief Financial Officer
(626) 293-3400
[email protected]

Media

Joel Counter
Director, Corporate & Marketing Communications
(626) 999-7017
[email protected]

The Company Holds a US Patent for the Same Treatment

FREMONT, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) — viaNewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a Taiwanese patent, Application No. 109130285, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company’s asset ABV-1504 for the treatment of Major Depressive Disorder (MDD). The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.

“These patents grant ABVC the right to exclude others from using, offering, or selling PDC-1421, throughout the United States and Taiwan until the year of 2040,” said Dr. Uttam Patil, ABVC Chief Executive Officer. “As our patent map steps into global coverage, we eagerly await the results of patent applications in the European Union, China, Japan, and more.”

The patent application was submitted to the Taiwan Patent and Trademark Office under the title “Polygala Extract for the Treatment of Major Depressive Disorder.” The invention relates to oral administration of the formulation containing a Radix Polygala (Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for treating Major Depressive Disorder. Based on current studies, administering the composition should be done over the course of at least 25 days, with the daily dose varying once, twice, or three times per day; each dose ranges between 380-760 mg of the botanical extraction.

ABV-1504, the Company’s asset indicated for use in MDD containing PDC-1421, is a botanical-based Norepinephrine Transporter (NET) inhibitor that has completed Phase II clinical studies, with plans to initiate an End of Phase II (EOP II) meeting with the FDA.

We believe the Company’s pipeline products have great market potential. As per the Future Market Insights report, the MDD market was valued at $11.51 billion in 2022 and is expected to reach $14.96 billion by 2032 with a CAGR of 2.8% over the forecast period.¹ According to the Polaris market research report, the global ADHD treatment market was valued at $16.13 billion in 2022 and is expected to reach $32.14 billion by 2030 with a CAGR of 7.1% over the forecast period.²

About ABVC BioPharma & Its Industry

ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company’s network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

Contact:

Tom Masterson
Email: [email protected]

[1] https://www.futuremarketinsights.com/reports/major-depressive-disorder-treatment-market#:~:text=The%…

[2] https://www.prnewswire.com/news-releases/global-attention-deficit-hyperactivity-disorder-adhd-market…

NEW YORK, Oct. 09, 2023 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced today that they have signed an agreement with the National Basketball Association (NBA) securing the rights to develop Virtual Sports games centered around the world’s premier professional basketball league’s archived footage.

The NBA-themed Virtual Sports offerings will provide fans the ability to wager on teams in fast-paced matchups. Users will have many of the same wagering options as a standard sportsbook including money line bets, over/under total score, etc. The NBA-themed Virtual Sports will include a variety of NBA imagery, including NBA archived footage and all 30 team logos, as well as during NBA All-Star, NBA Playoffs and NBA Finals.

The NBA is a global sports league and media organization that inspires and connects people everywhere through the power of basketball. The league is comprised of 30 teams across North America featuring the best basketball players in the world.

“We are thrilled to offer basketball fans worldwide the one-of-a-kind experience of a Virtual Sports NBA game. Our use of archived NBA footage will produce a truly distinct Virtual Sports offering, complete with fresh gaming experiences that provide a unique way for fans to stay connected with the game, even during the off-season,” stated Brooks Pierce, Inspired’s President and CEO. “Our partnership with the NBA allows us to provide an incredible offering that elevates our customers’ brands and expands their reach to millions of basketball enthusiasts worldwide.”

“Virtual sports gaming continues to grow in popularity across the globe,” stated Kuljeet Sindhar, Associate Vice President of International Gaming & Data Ventures at the NBA. “We’re excited to embark on this unique collaboration with Inspired Entertainment to engage our fans around virtual sports with real game action. Inspired is a leader in this space and will utilize immersive NBA game footage to deliver an authentic NBA experience to reach our fans in new and unique ways and continue to grow our fanbase around the world.”

Inspired’s multi award-winning Virtual Sports are popular worldwide, appealing to a wide variety of players through more than 40,000 retail channels and 100+ websites in 35 countries. To find out more about Inspired’s Virtuals, visit: https://inseinc.com/virtuals/

About Inspired Entertainment, Inc.

Inspired offers an expanding portfolio of content, technology, hardware and services for regulated gaming, betting, lottery, social and leisure operators across land-based and mobile channels around the world. Inspired’s gaming, Virtual Sports, interactive and leisure products appeal to a wide variety of players, creating new opportunities for operators to grow their revenue. Inspired operates in approximately 35 jurisdictions worldwide, supplying gaming systems with associated terminals and content for approximately 50,000 gaming machines located in betting shops, pubs, gaming halls and other route operations; virtual sports products through more than 32,000 retail venues and various online websites; digital games for 170+ websites; and a variety of amusement entertainment solutions with a total installed base of more than 16,000 terminals. Additional information can be found at www.inseinc.com.

Contacts:

Investor Relations

[email protected]

+1 646 277 1285